CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 195 filers reported holding CLOVIS ONCOLOGY INC in Q3 2018. The put-call ratio across all filers is 0.31 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $3,098,000 | +0.6% | 105,469 | +55.7% | 0.01% | 0.0% |
| Q2 2018 | $3,080,000 | -3.0% | 67,749 | +12.7% | 0.01% | 0.0% |
| Q1 2018 | $3,174,000 | -7.9% | 60,109 | +18.5% | 0.01% | 0.0% |
| Q4 2017 | $3,447,000 | -37.2% | 50,740 | -23.8% | 0.01% | -37.5% |
| Q3 2017 | $5,485,000 | +1234.5% | 66,560 | +1416.9% | 0.01% | +700.0% |
| Q2 2017 | $411,000 | +69.8% | 4,388 | +15.5% | 0.00% | – |
| Q1 2017 | $242,000 | +18.6% | 3,798 | -35.0% | 0.00% | – |
| Q4 2015 | $204,000 | -24.4% | 5,840 | +98.6% | 0.00% | -100.0% |
| Q3 2015 | $270,000 | +12.0% | 2,940 | +7.3% | 0.00% | – |
| Q2 2015 | $241,000 | +18.7% | 2,740 | 0.0% | 0.00% | – |
| Q1 2015 | $203,000 | -75.1% | 2,740 | -84.8% | 0.00% | -100.0% |
| Q3 2014 | $816,000 | -4.9% | 17,980 | -13.3% | 0.00% | 0.0% |
| Q2 2014 | $858,000 | +61.3% | 20,729 | +210.3% | 0.00% | +100.0% |
| Q1 2014 | $532,000 | +94.2% | 6,680 | +63.4% | 0.00% | 0.0% |
| Q2 2013 | $274,000 | – | 4,089 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 814,833 | $45,630,648,000 | 43.63% |
| EcoR1 Capital, LLC | 384,348 | $21,523,000 | 10.89% |
| Palo Alto Investors LP | 2,102,857 | $117,760,000 | 6.91% |
| NEA Management Company, LLC | 2,279,781 | $127,668,000 | 6.19% |
| Redmile Group, LLC | 721,632 | $40,411,000 | 4.40% |
| Opaleye Management Inc. | 140,000 | $7,840,000 | 3.96% |
| CLIFTON PARK CAPITAL MANAGEMENT, LLC | 790,555 | $44,271,000 | 2.63% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 339,327 | $19,002,000 | 2.31% |
| PFM Health Sciences, LP | 1,725,126 | $96,607,000 | 2.26% |
| HARBOURVEST PARTNERS LLC | 51,037 | $2,858,000 | 1.50% |